- Home
- LECO vs BBIO Comparison
LECO vs BBIO Comparison
Compare LECO & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LECO | BBIO |
|---|---|---|
| Founded | 1895 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9B | 15.3B |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LECO | BBIO |
|---|---|---|
| Price | $256.20 | $74.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 25 |
| Target Price | ★ $273.67 | $86.04 |
| AVG Volume (30 Days) | 325.2K | ★ 1.5M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | ★ 14.36 | N/A |
| EPS | ★ 9.32 | N/A |
| Revenue | ★ $3,761,211,000.00 | $502,076,000.00 |
| Revenue This Year | $8.65 | $88.16 |
| Revenue Next Year | $5.28 | $74.13 |
| P/E Ratio | $27.46 | ★ N/A |
| Revenue Growth | 16.30 | ★ 126.26 |
| 52 Week Low | $169.69 | $31.77 |
| 52 Week High | $310.00 | $84.94 |
Technical Indicators
Market Signals| Indicator | LECO | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 57.26 |
| Support Level | $253.07 | $70.65 |
| Resistance Level | $264.87 | $78.20 |
| Average True Range (ATR) | 7.01 | 2.54 |
| MACD | 1.46 | 0.48 |
| Stochastic Oscillator | 84.49 | 81.78 |
Price Performance
Historical ComparisonAbout LECO Lincoln Electric Holdings Inc.
Lincoln Electric is a leading manufacturer of welding, cutting, and brazing products. Its portfolio includes arc-welding solutions, plasma and oxy-fuel cutting systems, brazing and soldering alloys, and automation solutions. Lincoln Electric serves clients across general fabrication, heavy industries, automotive, construction, shipbuilding, energy, and process industries, among others. Based in Cleveland, Lincoln Electric operates in 19 countries and employs 11,000 worldwide. The company generated roughly $4.2 billion in sales in 2025.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.